6569 | 醫揚 - Stock Value & PE Ratio Analysis

3

24

15

Average Growth

AI analysis rates 6569 with a medium value score of 3.
It is mainly due to stable revenue growth, but with concerns regarding unstable operating cash flow.
Over the past 3 months, 6569 has maintained an average value rating of 2.7, slightly lower than the rating of 3.8 over the past 3 years, indicating decreasing growth opportunities for enterprise value.
Compared to all stocks in the Biotech. & Medical sector, 6569 has a medium value rating.

6569 Value Reference Factors

The Value score is derived from various data and factor information, integrated through AI algorithms. The following factors are part of the evaluation used by AI value scores.

Update to 2025/05/09 (Weekly Update)

6569 Financial Forecast

Unit : TWD

Update to 2025/5/13 (Quarterly Update)

6569 Earnings Table

Unit : TWD

QTR	Non-GAAP EPS	EPS YoY	EPS Surprise %	Sales	Sales YoY	Sales Surprise %	NPM
Current	0.19	-87.5%	-	309.94M	12.6%	-	2.4%
2024Q4	1.68	-15.6%	-	382.57M	-12%	-	16.9%
2024Q3	0.69	-64.8%	-	284.01M	-23.7%	-	9.4%
2024Q2	1.15	-43.3%	-	299.34M	-16.4%	-	12.9%
2024Q1	1.52	-10.1%	-	275.34M	-16%	-	18.2%

Update to 2025/5/14 (Quarterly Update)

6569 Historical Value Score

You can use historical scores of 3 or above to observe potential performance and make investment decisions.

6569 Value Strategy Backtest

The following backtest is based on specified rules since 2007. Price chart shows buy/sell time, cumulative returns, and backtesting statistics.

Entry

Exit

The Backtest Result of 6569 from 2016/12 till Now

139.34%
Cumulative Return: 11.39%
Annual Return: 24.78%
Volatility: 0.46
Sharpe Ratio

Statistics data for entering at or above a Value score of 4 and exiting at or below a Value score of 2 from December, 2016 to May, 2025. (Total Trades: 2)